

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company" or "Avita Medical")
ABN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Perry
Date of last notice	3 March 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/a
Date of change	1 June 2022 (United States) / 2 June 2022 (Australia)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>634,602 CDIs in the Company quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in the Company)</p> <p>75,845 Shares</p> <p>89,320 unquoted RSUs in the Company</p> <p>55,200 unquoted options in the Company</p> <p>Dr Perry holds the following convertible securities in Avita Australia, being a wholly owned subsidiary of the Company:</p> <ul style="list-style-type: none"> • 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in the Company) • 4,750,749 unquoted RSUs in Avita Australia (consolidation equivalent = 47,507 unquoted RSUs in the Company) <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued shares in the Company (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020.</p>
Class	As above
Number acquired	47,507 Shares (which do not presently have CDIs issued over them and therefore not quoted on ASX) acquired on 1 June 2022 (United States) / 2 June 2022 (Australia).

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	4,750,749 unquoted RSUs in Avita Australia (consolidation equivalent = 47,507 RSUs in the Company) which were converted into 47,507 Shares that were issued on 1 June 2022 (United States) / 2 June 2022 (Australia).
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Acquisition of 47,507 Shares - nil consideration (issued as a result of the vesting of the relevant tranche of Dr Perry's unquoted RSUs in Avita Australia as noted above).

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p>	<p>634,602 CDIs in the Company quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in the Company)</p> <p>123,352 Shares*</p> <p>89,320 unquoted RSUs in the Company</p> <p>55,200 unquoted options in the Company</p> <p>Dr Perry holds the following convertible securities in Avita Australia, being a wholly owned subsidiary of the Company:</p> <ul style="list-style-type: none"> • 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in the Company) <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued shares in the Company (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020.</p> <p><i>*23,753 shares of the 47,507 issued will be transferred to the former spouse of Dr Perry. Post the transfer, Dr Perry will hold 99,599 Shares.</i></p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Acquisition on 1 June 2022 (United States) / 2 June 2022 (Australia) – conversion of unquoted RSUs in Avita Australia and the Company (as applicable)</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	<p>N/a</p>
<p>Nature of interest</p>	<p>N/a</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	N/a
Date of change	N/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/a
Interest acquired	N/a
Interest disposed	N/a
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/a
Interest after change	N/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

+ See chapter 19 for defined terms.